Saving private practice? Navigating the legal and ethical minefield of physician-private equity deals
Saving private practice? Navigating the legal and ethical minefield of physician-private equity deals
While physicians face incredible pressures to consolidate or receive investment to survive, there are ethical, legal and practical considerations doctors must seriously consider before deciding to take private equity.
Shares0
While physicians face incredible pressures to consolidate or receive investment to survive, there are ethical, legal and practical considerations doctors must seriously consider before deciding to take private equity. How can they get the investment they need to keep their doors open without ending up drowning in litigation?
Share this article
Share this article
NEW YORK, March 16, 2021 /PRNewswire/ The Covid-19 pandemic rocked global healthcare systems and communities to their core in 2020. Healthcare investors realized a Covid-19 paradox, facing urgent, widespread need for innovation and more equitable access to healthcare services as well as sharp repercussions for demand. Nonetheless, healthcare private equity showed remarkable resilience last year. In contrast to the overall private equity market, healthcare private equity deal volume rose to record levels, increasing by 21% to a total of 380 deals in 2020. Ample dry powder, along with capital markets strong appetite for exits, created fertile conditions for investment. These are the findings from Bain & Company s tenth
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board
BARCELONA, Spain, Jan. 07, 2021 Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive
Giacomo Di Nepi as
Mr. Di Nepi has accumulated nearly
40 years of global experience in the Healthcare sector. His career started with 16 years at McKinsey & Company, where he was a Partner and Core Leadership member of the Global Pharmaceutical Practice, followed by 11 years at
You won’t want to miss four days of exclusive, virtual events that bring together industry leaders, emerging standouts, innovators and investors from across the industry landscape at the largest healthcare investment symposium.
Healthcare leaders will address comprehensive trends and implications faced in Digital Health, Life Sciences, Healthcare Private Equity (PE) and Hospitals and Health Systems (HHS). Develop an effective, long-term strategy through the post-pandemic period while forging deals and funding agreements to impact the industry’s future.
Follow the registration link here and below to sign-up and learn more about the full event.
AGENDA
You won’t want to miss four days of exclusive, virtual events that bring together industry leaders, emerging standouts, innovators and investors from across the industry landscape at the largest healthcare investment symposium.
Healthcare leaders will address comprehensive trends and implications faced in Digital Health, Life Sciences, Healthcare Private Equity (PE) and Hospitals and Health Systems (HHS). Develop an effective, long-term strategy through the post-pandemic period while forging deals and funding agreements to impact the industry’s future.
Follow the registration link here and below to sign-up and learn more about the full event.
AGENDA